The phase 2 and phase 3 clinical trials use a systemic stepwise titration to gradually increase the retatrutide dose to help the body adjust and reach the therapeutically effective dose with minimal side effects
As GLP-1 therapies evolve, semaglutides established efficacy and adaptability continue to define its role as a leading option for medically supervised weight loss in 2026
For reasons that still aren't understood, the same drug works far better for some people than for others
Conflict of interest The author has provided advisory services to AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, and Novo Nordisk, and has received lecture honoraria from Bristol Myers Squibb, Novartis and the above-mentioned companies
This surgery is not exempt from complications: persistence of hypoglycaemia episodes, nausea and vomiting or limitations in oral tolerance, weight regain and gastro-oesophageal reflux
Heres how to bring it all together: 1